Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- (-) Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- (-) Health Spending
- Health Spend Management
- High-Deductible Health Plans
- (-) Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- (-) Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 180 Results
NPC in Chain Drug Review: The Impact of PBM Rebates at the Pharmacy Counter
There is a mismatch between the savings pharmacy benefit managers (PBMs) boast about and the pinch patients are feeling in their pockets, as well as the disconnect between the role employers…
Paying for Patient Care: Understanding the Costs and Benefits Now and Later
A new infographic based on a National Pharmaceutical Council peer-reviewed study explains how gaps between upfront costs and long-term savings of innovative treatments can emerge, why we need to…
NPC in Morning Consult: “Why Is Drug Spending So High?” Is the Wrong Question
In a column published in Morning Consult, NPC Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, explains that asking why drug spending is so high assumes that…
National Pharmaceutical Council in STAT: The (relative) risk in misinterpreting health spending statistics
National Pharmaceutical Council Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, explains in his column in STAT that the absolute numbers tell a different story than the…
Health Care Spending Expected to Increase, According to Latest CMS Figures
National health care spending is expected to increase to $5.7 trillion and comprise nearly 20% of the Gross Domestic Product by 2026, according to the latest statistics reported today by the Centers…
Health Spending: Tackling the Big Issues
The Health Affairs and National Pharmaceutical Council event, “Health Spending: Tackling the Big Issues,” convened a crowd of more than 450 to ask critical questions about how the United States…
Peer-reviewed Journal Editors' Views on Real-world Evidence
A study published in the International Journal of Technology Assessment in Health Care reveals that real-world evidence is considered valuable by the editors of peer-reviewed journals—if it meets…
Tackling the Big Issues in Health Spending
The Health Affairs and National Pharmaceutical Council event, “Health Spending: Tackling the Big Issues,” convened a crowd of more than 450 to ask critical questions about how the United States…
NPC in AJPB: Having a Broader Conversation About Health Care Spending
In his latest column for the American Journal of Pharmacy Benefits, National Pharmaceutical Council President Dan Leonard argues it’s time for us to have a broader, more honest conversation…
Biopharma Innovation Just Part Of Health Care Equation
Biopharma discoveries are changing people's lives in ways we didn't know were possible just a decade ago. As the industry's science continually expands the treatment frontier, the business of health…
Where Are They Now: Checking In With Former NPC Intern Jan Hansen
Jan Hansen, PhD, currently Vice President, Evidence for Access Medical Unit, US Medical Affairs at Genentech, participated in NPC’s pharmaceutical internship program in 1982. Dr. Hansen chatted with…
Insurance Switching and the Mismatch Between the Costs and Benefits of New Technologies
The peer-reviewed study examined the disconnect between the short-term budget impact of a treatment and its downstream effects on payers and society.